Cytosorbents Corp presented its business strategy during the Life Sciences Forum, focusing on a restructuring of the German sales team and a strategic workforce reduction plan. The presentation highlights the company’s objectives to achieve operating cash-flow break-even in 2026 and clarifies the currently investigational status of its device in the U.S.